CLNN vs. RMTI, BOLT, RVPH, IMRX, BLRX, AADI, NBRV, RPHM, NXTC, and EQ
Should you be buying Clene stock or one of its competitors? The main competitors of Clene include Rockwell Medical (RMTI), Bolt Biotherapeutics (BOLT), Reviva Pharmaceuticals (RVPH), Immuneering (IMRX), BioLineRx (BLRX), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Reneo Pharmaceuticals (RPHM), NextCure (NXTC), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
Rockwell Medical (NASDAQ:RMTI) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Rockwell Medical has higher revenue and earnings than Clene. Rockwell Medical is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rockwell Medical had 16 more articles in the media than Clene. MarketBeat recorded 22 mentions for Rockwell Medical and 6 mentions for Clene. Rockwell Medical's average media sentiment score of 0.27 beat Clene's score of 0.10 indicating that Clene is being referred to more favorably in the news media.
Rockwell Medical currently has a consensus price target of $7.00, indicating a potential upside of 296.60%. Clene has a consensus price target of $6.50, indicating a potential upside of 1,656.76%. Given Rockwell Medical's higher possible upside, analysts clearly believe Clene is more favorable than Rockwell Medical.
Rockwell Medical received 244 more outperform votes than Clene when rated by MarketBeat users. However, 75.32% of users gave Clene an outperform vote while only 57.31% of users gave Rockwell Medical an outperform vote.
Rockwell Medical has a net margin of -9.72% compared to Rockwell Medical's net margin of -7,873.23%. Clene's return on equity of -28.29% beat Rockwell Medical's return on equity.
Rockwell Medical has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Clene has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.
23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 1.9% of Rockwell Medical shares are owned by company insiders. Comparatively, 25.1% of Clene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Rockwell Medical beats Clene on 10 of the 17 factors compared between the two stocks.
Get Clene News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
